Literature DB >> 15541373

High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656.

John M Ridley1, James T Milnes, Harry J Witchel, Jules C Hancox.   

Abstract

Pharmacological inhibition of human-ether-a-go-go-related gene (HERG) K(+) channels by structurally and therapeutically diverse drugs is associated with the 'acquired' form of long QT syndrome and with potentially lethal cardiac arrhythmias. Two aromatic amino-acid residues (Y652 and F656) on the inner (S6) helices are considered to be key constituents of a high affinity drug binding site within the HERG channel pore cavity. Using wild-type (WT) and mutant HERG channels expressed in mammalian cell lines, we have investigated HERG channel current (I(HERG)) blockade at 37+/-1 degrees C by dronedarone (DRONED), a non-iodinated analogue of the Class III antiarrhythmic agent amiodarone (AMIOD). Under our conditions WT I(HERG) tails, measured at -40 mV following activating pulses to +30 mV, were blocked with IC(50) values of approximately 59 and 70 nM for DRONED and AMIOD, respectively. I(HERG) inhibition by DRONED was contingent upon channel gating, with block developing rapidly on membrane depolarization, but with no preference for activated over inactivated channels. High external [K(+)] (94 mM) reduced the potency of I(HERG) inhibition by both DRONED and AMIOD. Strikingly, mutagenesis to alanine of the S6 residue F656 (F656A) failed to eliminate blockade by both DRONED and AMIOD, whilst Y652A had comparatively little effect on DRONED but some effect on AMIOD. These findings demonstrate that high affinity drug blockade of I(HERG) can occur without a strong dependence on the Y652 and F656 aromatic amino-acid residues.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15541373     DOI: 10.1016/j.bbrc.2004.10.127

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  High potency inhibition of hERG potassium channels by the sodium-calcium exchange inhibitor KB-R7943.

Authors:  Hongwei Cheng; Yihong Zhang; Chunyun Du; Christopher E Dempsey; Jules C Hancox
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.

Authors:  M J McPate; R S Duncan; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  2008-08-25       Impact factor: 8.739

3.  Predicting the potency of hERG K⁺ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models.

Authors:  Yayu Tan; Yadong Chen; Qidong You; Haopeng Sun; Manhua Li
Journal:  J Mol Model       Date:  2011-06-10       Impact factor: 1.810

Review 4.  Activation of human ether-a-go-go related gene (hERG) potassium channels by small molecules.

Authors:  Ping-zheng Zhou; Joseph Babcock; Lian-qing Liu; Min Li; Zhao-bing Gao
Journal:  Acta Pharmacol Sin       Date:  2011-05-30       Impact factor: 6.150

5.  A critical assessment of combined ligand- and structure-based approaches to HERG channel blocker modeling.

Authors:  Lei Du-Cuny; Lu Chen; Shuxing Zhang
Journal:  J Chem Inf Model       Date:  2011-10-13       Impact factor: 4.956

6.  Role of the activation gate in determining the extracellular potassium dependency of block of HERG by trapped drugs.

Authors:  Kristeen Pareja; Elaine Chu; Katrina Dodyk; Kristofer Richter; Alan Miller
Journal:  Channels (Austin)       Date:  2012-12-06       Impact factor: 2.581

7.  Molecular determinants of hERG channel block by terfenadine and cisapride.

Authors:  Kaichiro Kamiya; Ryoko Niwa; Mikio Morishima; Haruo Honjo; Michael C Sanguinetti
Journal:  J Pharmacol Sci       Date:  2008-11-06       Impact factor: 3.337

8.  The amiodarone derivative KB130015 activates hERG1 potassium channels via a novel mechanism.

Authors:  Guido Gessner; Regina Macianskiene; John G Starkus; Roland Schönherr; Stefan H Heinemann
Journal:  Eur J Pharmacol       Date:  2010-01-25       Impact factor: 4.432

9.  Cardiovascular pharmacology of K2P17.1 (TASK-4, TALK-2) two-pore-domain K+ channels.

Authors:  Ingo Staudacher; Claudius Illg; Sam Chai; Isabelle Deschenes; Sebastian Seehausen; Dominik Gramlich; Mara Elena Müller; Teresa Wieder; Ann-Kathrin Rahm; Christina Mayer; Patrick A Schweizer; Hugo A Katus; Dierk Thomas
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-07-14       Impact factor: 3.000

10.  Mechanism of hERG K+ channel blockade by the fluoroquinolone antibiotic moxifloxacin.

Authors:  Ari J Alexandrou; Rona S Duncan; Anneli Sullivan; Jules C Hancox; Derek J Leishman; Harry J Witchel; Joanne L Leaney
Journal:  Br J Pharmacol       Date:  2006-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.